Rhabdomyolysis and Compartment Syndrome with Coadministration of Risperidone                 and Simvastatin

Webber, Michael A.; Mahmud, Waqar; Lightfoot, Jeffery D.; Shekhar, Anantha

doi:10.1177/026988110401800316

Cited by 34 publications

(17 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…risk-scoring system for patients with SMI (Taxis et al 2008;De Hert et al 2009). Even if an adapted risk score system would be available for patients with SMI, implementation of somatic treatment regimens may be complicated by pharmacokinetic inter actions between statins and antipsychotics (Baptista et al 2004;Webber et al 2004) or by adverse somatic eff ects induced by β -adrenergic antagonists and thiazide diuretics, such as weight gain and glucose dysregulation (Sharma et al 2001;Elliot and Meyer 2007).…”

Section: Discussionmentioning

confidence: 99%

Cardiometabolic comorbidity in antipsychotic treated patients: need for systematic evaluation and treatment

Steylen

Heijden

Kok

et al. 2013

International Journal of Psychiatry in Clinical Practice

View full text Add to dashboard Cite

Cardiometabolic risk factors are highly prevalent in psychiatric patients treated with antipsychotic drugs. Unfortunately, adequate treatment of cardiometabolic comorbidity in these relatively young patients is seriously hampered. Thus, specific guidelines for psychiatric patients have to be developed taking into account the high cardiovascular risk at a relatively young age and potential pharmacokinetic interactions between psychotropics and somatic compounds. Moreover, integration of psychiatric and physical health care systems for patients with mental disorders is urgently needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Cardiometabolic comorbidity in antipsychotic treated patients: need for systematic evaluation and treatment

Steylen

Heijden

Kok

et al. 2013

International Journal of Psychiatry in Clinical Practice

View full text Add to dashboard Cite

show abstract

“…No studies have yet been published on the efficacy of statins in the treatment of antipsychotic-related dyslipidemias, although a few case reports on individual patients have described some possible side effects for the co-administration of SGAs (risperidone, quetiapine) with statins (Furst et al, 2002;Giner et al, 2002;Webber et al, 2004). Further, recent guidelines suggest frequent monitoring of cardiovascular risk factors in patients with schizophrenia, but this sort of monitoring begets the question of how to treat such disorders, especially in cases that have an unfavorable lipid profile.…”

mentioning

confidence: 99%

Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents

et al. 2007

View full text Add to dashboard Cite

Statins are widely used in the treatment of patients having high levels of serum total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C). However, there is little documentation on the ability of statins to treat dyslipidemia induced by second-generation antipsychotics (SGAs) and if so, to what extent. A goal of the present study was to evaluate these aspects among psychotic inpatients who were prescribed SGAs in a typical clinical setting. The study sample consisted of 28 psychotic male forensic psychiatric inpatients (mean age 44 years). All had sGA medication for their psychotic symptoms. secondary causes of dyslipidemia were excluded and statin therapy was initiated, according to the established guidelines. The change in TC, LDL-C, high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) levels were evaluated retrospectively and analysed by the Wilcoxon signed Ranks test. The lowering effectivity of statin treatment was 36% for TC, 49% for LDL-C and 29% for TG. Most of the patients (84%) achieved a target value for LDL-C of <3.0 mmol/L, and 54% achieved target value of <2.6 mmol/L, while HDL-C remained unchanged. These results were achieved with a low or moderate dose of statin during a period of 1 month. The effect of statins in lowering of TC, LDL-C and TG among dyslipidemic psychiatric patients that were treated with sGA was similar to the effectiveness of statin therapy in other clinical trial settings, and should be used when they are indicated.

show abstract

“…One was in a patient with newly diagnosed hypothyroidism,4 a known cause of spontaneous compartment syndrome. The second, a review of a patient originally diagnosed with rhabdomyolysis5 and the final case a result of drug interaction between simvastatin and risperidone 6…”

Section: Discussionmentioning

confidence: 99%

Spontaneous compartment syndrome in association with simvastatin-induced myositis

Walker

Smith

Gaston

et al. 2008

Emergency Medicine Journal

View full text Add to dashboard Cite

Compartment syndrome as a result of simvastatin-induced myositis is extremely rare. This case discusses a patient with spontaneous onset compartment syndrome that necessitated four-compartment fasciotomy. A thorough investigation into its cause highlighted statin-induced myositis as the most likely aetiological agent. When investigating a patient with unexplained spontaneous compartment syndrome it is important to consider drug-induced myositis. This case reinforces the difficulty faced in diagnosing spontaneous compartment syndrome.

show abstract

Rhabdomyolysis and Compartment Syndrome with Coadministration of Risperidone and Simvastatin

Cited by 34 publications

References 13 publications

Cardiometabolic comorbidity in antipsychotic treated patients: need for systematic evaluation and treatment

Cardiometabolic comorbidity in antipsychotic treated patients: need for systematic evaluation and treatment

Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents

Spontaneous compartment syndrome in association with simvastatin-induced myositis

Contact Info

Product

Resources

About